This company has been acquired
Resumen de acción AVEO
AVEO Pharmaceuticals, Inc., an oncology-focused biopharmaceutical company, focuses on developing and commercializing medicines for patients with cancer.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
No se han detectado riesgos en AVEO a partir de nuestros controles de riesgos.
Competidores de AVEO Pharmaceuticals, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.00 |
| 52 Week High | US$15.00 |
| 52 Week Low | US$3.06 |
| Beta | 0.98 |
| 1 Month Change | 0.47% |
| 3 Month Change | 1.63% |
| 1 Year Change | 338.60% |
| 3 Year Change | 153.81% |
| 5 Year Change | -50.33% |
| Change since IPO | -83.31% |
Noticias y actualizaciones recientes
Recent updates
AVEO Oncology shares jumped on acqusition by LG Chem for $15.00 per share in cash
Oct 18Here's Why AVEO Pharmaceuticals (NASDAQ:AVEO) Can Manage Its Debt Despite Losing Money
Oct 04
A Current Assessment On AVEO Pharmaceuticals
Aug 15Rock star Growth Puts AVEO Pharmaceuticals (NASDAQ:AVEO) In A Position To Use Debt
Jun 21AVEO Pharmaceuticals Is Primed For A Breakout
May 24Here's What Analysts Are Forecasting For AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) After Its Annual Results
Mar 17AVEO Pharmaceuticals: Finally Ready To Reboot
Mar 09AVEO Pharmaceuticals (NASDAQ:AVEO) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Mar 03AVEO Pharmaceuticals (NASDAQ:AVEO) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Nov 23AVEO Pharmaceuticals: Sticking To The Plan
Oct 29AVEO Pharmaceuticals: Making Its Mark In Cancer Treatment
Jul 24AVEO Oncology: Time To Be Patient
Jun 07AVEO outlines 2021 outlook; initiates Phase 1 trial for cancer complication
Jan 07AVEO Oncology: Managing A Position Ahead Of Tivozanib's PDUFA
Dec 27Rentabilidad de los accionistas
| AVEO | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | 0.1% | 4.7% | 0.7% |
| 1Y | 338.6% | 2.7% | 23.9% |
Rentabilidad vs. Industria: AVEO exceeded the US Biotechs industry which returned 7.2% over the past year.
Rentabilidad vs. Mercado: AVEO exceeded the US Market which returned -11.7% over the past year.
Volatilidad de los precios
| AVEO volatility | |
|---|---|
| AVEO Average Weekly Movement | 0.4% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: AVEO's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: AVEO's weekly volatility has decreased from 11% to 0% over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2001 | 114 | Michael Bailey | www.aveooncology.com |
Resumen de fundamentos de AVEO Pharmaceuticals, Inc.
| Estadísticas fundamentales de AVEO | |
|---|---|
| Capitalización bursátil | US$521.45m |
| Beneficios(TTM) | -US$29.04m |
| Ingresos (TTM) | US$94.32m |
5.5x
Ratio precio-ventas (PS)-18.0x
Ratio precio-beneficio (PE)¿Está AVEO sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de AVEO | |
|---|---|
| Ingresos | US$94.32m |
| Coste de los ingresos | US$37.79m |
| Beneficio bruto | US$56.53m |
| Otros gastos | US$85.56m |
| Beneficios | -US$29.04m |
Últimos beneficios comunicados
Sep 30, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.84 |
| Margen bruto | 59.93% |
| Margen de beneficio neto | -30.79% |
| Ratio deuda/patrimonio | 134.1% |
¿Cómo se ha desempeñado AVEO a largo plazo?
Ver rendimiento histórico y comparativa